|
|
Article: Graceway Pharmaceuticals Acquires Worldwide Rights to GS 9191 from Gilead Sciences.
- Article from:
- Business Wire
- Article date:
- November 6, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BRISTOL, Tenn. -- Graceway Pharmaceuticals, LLC, a portfolio company of GTCR Golder Rauner, LLC, today announced that the company has acquired from Gilead Sciences, Inc. the worldwide license, including related regulatory filings and intellectual properties, to Gilead's investigational molecule, GS 9191, for topical use. GS 9191 is an anti-proliferative agent that works by inhibiting cellular DNA synthesis, leading to the induction of apoptosis, or programmed cell death.
"This acquisition is further evidence of Graceway's proven practice of working with industry leading companies, like Gilead, to acquire and develop cutting edge compounds and technologies. The ...
Related newspaper, magazine, and journal articles:
|
|
Article: GTCR Announces Graceway Pharmaceuticals' Agreement ...
Business Wire;
November 9, 2006 ;
700+ words
... ... announced today that Graceway Pharmaceuticals Inc. ("Graceway ... acquisition. About Graceway Pharmaceuticals, Inc. Graceway Pharmaceuticals, headquartered in ... Founded in 1980, GTCR Golder Rauner, LLC is a ...
|
|